A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
Public ClinicalTrials.gov record NCT02924883. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with HER2-positive locally advanced or metastatic BC who have received prior trastuzumab and taxane based therapy, either alone or in combination, and/or who have progressed within 6 months after completing adjuvant therapy.
Study identification
- NCT ID
- NCT02924883
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 26, 2016 (Actual)
- Primary completion
- Dec 11, 2017 (Actual)
- Completion
- Feb 6, 2020 (Actual)
- Last update posted
- Feb 17, 2021
2016 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Breastlink Med Group Inc | Orange | California | 92868 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) | Washington D.C. | District of Columbia | 20007 | — |
| SCRI Florida Cancer Specialists South | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists; Saint Petersburg | St. Petersburg | Florida | 33719 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Johns Hopkins Univ Med Center | Baltimore | Maryland | 21231 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Laura and ISAAC Perlmutter Cancer Center at NYU Langone. | New York | New York | 10016 | — |
| Ohio State Uni Medical Center | Columbus | Ohio | 43210 | — |
| Magee Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Cancer Care Associates of York | York | Pennsylvania | 17403 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology; Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02924883, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2021 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02924883 live on ClinicalTrials.gov.